Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jerash Holdings (US) (JRSH) Cash & Equivalents (2016 - 2025)

Jerash Holdings (US) (JRSH) has disclosed Cash & Equivalents for 10 consecutive years, with $11.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 22.52% year-over-year to $11.5 million, compared with a TTM value of $11.5 million through Dec 2025, down 22.52%, and an annual FY2025 reading of $13.3 million, down 4.92% over the prior year.
  • Cash & Equivalents was $11.5 million for Q4 2025 at Jerash Holdings (US), down from $12.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $33.1 million in Q4 2021 and bottomed at $5.8 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $17.9 million, with a median of $18.2 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents crashed 56.88% in 2021, then skyrocketed 180.82% in 2022.
  • Year by year, Cash & Equivalents stood at $33.1 million in 2021, then dropped by 25.6% to $24.6 million in 2022, then fell by 20.34% to $19.6 million in 2023, then decreased by 24.64% to $14.8 million in 2024, then decreased by 22.52% to $11.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for JRSH at $11.5 million in Q4 2025, $12.0 million in Q3 2025, and $5.8 million in Q2 2025.